CJC-1295

Growth hormone support peptide

$250/mo

Virtual consult required

This peptide requires a brief virtual visit before our team can prescribe.

Details

Virtual Consult

Our licensed provider reviews your health profile via secure video — typically 10 minutes. Required for any peptide prescription.

Refund Policy: If found not eligible due to health reasons after consultation, you will receive a full refund.

Product Details

About CJC-1295

Mechanism of Action

CJC-1295 is a GHRH analog that stimulates the pituitary gland to increase natural HGH and IGF-1 production. Its Drug Affinity Complex (DAC) modification allows albumin binding, extending half-life from minutes to 6-8 days. The peptide maintains natural pulsatile GH release while increasing amplitude, promoting protein synthesis, fat breakdown, and tissue repair.

Scientific Background

Developed in the early 2000s, CJC-1295 can increase mean growth hormone levels by 200-1000% with corresponding IGF-1 elevation. Unlike direct HGH, it works within the body's natural feedback systems. Most commonly combined with GHRPs like Ipamorelin for synergistic effects—the combination produces significantly more GH than either alone.

Clinical Applications

Used for anti-aging, muscle growth, fat loss, and improved recovery. Frequently combined with Ipamorelin to maximize GH release while minimizing side effects. Users report improvements in skin quality, sleep, energy, and cognitive function. Effects typically noticeable within 2-4 weeks, with optimal benefits at 3-6 months.

Evidence-Based

Clinical Research & Studies

Backed by peer-reviewed research from leading medical journals

2005

Peer Reviewed

CJC-1295 DAC extends growth hormone release and IGF-1 levels

Study demonstrating CJC-1295 produces dose-dependent increases in growth hormone and IGF-1 levels lasting up to 13 days after a single injection, with sustained elevation of mean GH concentrations.

Read Full Study

2004

Peer Reviewed

Long-acting growth hormone releasing factor analog increases body mass in rats

Research showing CJC-1295 treatment resulted in increased lean body mass, improved body composition, and enhanced protein synthesis without adverse effects on glucose metabolism.

Read Full Study

2006

Peer Reviewed

Safety and tolerability of CJC-1295 in healthy subjects

Phase I clinical trial confirming CJC-1295's safety profile with sustained increases in GH and IGF-1, demonstrating predictable pharmacokinetics and minimal adverse events.

Read Full Study

CJC-1295

About CJC-1295

How It Works

Mechanism of Action

Scientific Background

Clinical Applications

Key Benefits

Treatment Protocol

Safety & Considerations

Clinical Research & Studies

CJC-1295 DAC extends growth hormone release and IGF-1 levels

Long-acting growth hormone releasing factor analog increases body mass in rats

Safety and tolerability of CJC-1295 in healthy subjects

Related Resources

Similar Peptide Therapies

Tesamorelin/Ipamorelin

IGF-1 LR3

BPC-157

Educational Articles

Growth Hormone Peptides: CJC-1295 and Ipamorelin Explained

Natural Growth Hormone Optimization for Anti-Aging